"Estonia Pharmaceuticals & Healthcare Report Q4 2014" is now available at Fast Market Research

Against a backdrop of GDP contraction in Q114, Estonian pharmacy sales posted considerable growth, driven by demand for over-the-counter medicines and an uptick in prescriptions written. Private consumer spending will continue to bolster pharmaceutical sales in 2014 as wage growth continues. Despite this data, Estonia will continue to remain a marginal market in the Central and Eastern European region. Whether or not a fiscally conservative policy in healthcare spending can survive Estonia's ageing population and the subsequent growth in demand for medicine is highly dependent on broader macroeconomic trends. Nevertheless, there are also potential rewards in the market. Any growth in demand for medicine is highly dependent on unemployment levels and the raising of premiums by the HIF.

Full Report Details at
- http://www.fastmr.com/prod/878953_estonia_pharmaceuticals_healthcare_report_q4_2014.aspx?afid=302

Headline Expenditure Projections

* Pharmaceuticals: From EUR276mn (USD364mn) in 2013 to EUR289mn (USD387mn) in 2014; +4.7% in local currency terms and +6.2% in US dollar terms. The local currency growth forecast of 4.7% in 2014 is a decrease after 2013's 5.3%, with the forecast continuing on a long-term decline after 2014. The 2014 local currency forecast also represents a marked decline from the growth of 9.2% in 2012 due to new market data and macroeconomic expectations.
* Healthcare: EUR1.08bn (USD1.42bn) in 2013 to EUR1.13bn (USD1.51bn) in 2014; +4.2% in local currency terms and +5.8% in US dollar terms .

Risk/Reward Ratings

Estonia scores 52.1 out of 100 in BMI's Pharmaceutical Risk/Reward Rating (RRR) tool, remaining in 10 ^th position out of the 20 key markets covered in Central and Eastern Europe. Estonia's Industry Rewards score is still the weakest part of its pharmaceutical profile, at now 12.8 after 11.6 in Q314, significantly below the regional average of 18.8. That it scores as high as it does is mainly due to above-average scores in the urban/rural split and pensionable population. As the population ages, the dominant types of disease will...

The Estonia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Estonia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Estonian pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Estonia to test other views - a key input for successful budgeting and strategic business planning in the Estonian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014
- Argentina Pharmaceuticals & Healthcare Report Q4 2014
- Peru Pharmaceuticals & Healthcare Report Q4 2014